The following members were elected for the next four years:
Liselotte Hyveled
Anne Marie Kverneland
Søren Thuesen Pedersen
Stig Strøbæk
As substitutes to the employee representatives to the Board of Directors of Novo Nordisk A/S, the employees elected Desirée J. Asgreen, Mette Bøjer Jensen, Anders Kaae and Michael Munksø.
The new employee representatives will join the Board of Directors following the annual general meeting of Novo Nordisk A/S, 20 March 20 2014. At the same event, the former employee representatives, Ulrik Hjulmand-Lassen will withdraw from the Board of Directors.
According to the Danish Companies Act, the employees in companies, which have for the last three years employed at least 35 employees on average, have a right to elect a number of members to the board of directors. The employee-elected board members shall represent a number that corresponds to at least half of the board members elected by the annual general meeting. Furthermore, substitutes corresponding to the number of employee-elected board members must be elected. The employee-elected board members act on the same terms as the board members elected by the annual general
meeting, but are elected for a four-year period.
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 12 / 2014
Page 2 of 2
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B
shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.
Further information Media: Mike Rulis Ken Inchausti (US) | +45 4442 3573 +1 609 514 8316 | mike@novonordisk.com kiau@novonordisk.com |
Investors: Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen Jannick Lindegaard (US) | +45 3079 0604 +45 3075 3479 +45 3079 6376 +1 609 235 8567 | fdni@novonordisk.com lbpj@novonordisk.com dabo@novonordisk.com jlis@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 12 / 2014
distributed by |